Medical Devices - Cardiovascular Intervention & Stroke Prevention
Strategic Profile
The company's MicroNet stent technology integrates a self-expandable nitinol stent with an innovative mesh structure designed to reduce embolic events during carotid interventions, enhancing both immediate and long-term patient outcomes. InspireMD's business model revolves around direct sales of innovative stent systems, and the company has streamlined manufacturing and enhanced operational capabilities in strategic regions, with its new U.S. headquarters established to strengthen commercial infrastructure.
Cyborg Score Rationale
The company is operating at a net loss of -$32 million on trailing twelve months basis, while having achieved FDA approval and commercial launch of its primary product in July 2025. The company shows promise with regulatory validation but faces profitability challenges typical of early-stage medical device commercialization.
Top Insights
FDA approval and U.S. commercial launch of CGuard Prime in July 2025 represents critical inflection point for revenue growth
Company secured $58 million in combined financing (PIPE and warrant exercises) in late 2024 to fund U.S. launch and operations
Current financial position shows early-stage commercialization: $7M annual revenue against $32M net loss with strong liquidity ($26M cash as of March 2025)
Market cap of ~$88.6M reflects modest valuation for early-revenue medical device company with global market opportunities
Named Competitors
Embolic Prevention Devices — Leading carotid stent platform with extensive market share in North America
Carotid Artery Stents — Established player with comprehensive vascular intervention portfolio
Vascular Intervention Systems — Large diversified medical device company with competing stroke prevention solutions
Recent Developments
(July 2025) Official commercial launch of CGuard Prime carotid stent system in U.S. following FDA approval
(December 2024) First patient enrolled in CGUARDIANS II pivotal study for CGuard Prime in TCAR procedures
(October 2024) Establishment of global headquarters in Miami, Florida to support U.S. launch and commercialization
(September 2024) Submission of Premarket Approval (PMA) application to FDA for CGuard Prime carotid stent system
Open the full interactive InspireMD, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.